I agree that this site is using cookies. You can find further informations here.
X
Oniangue-Ndza, Cesar
17  results:
?
1

Cost-Effectiveness of Nivolumab Plus Ipilimumab for the Fir..:

Çakar, Esra ; Oniangue-Ndza, César ; Schneider, Ralph P....
PharmacoEconomics - Open.  7 (2023)  4 - p. 567-577 , 2023
Link: https://doi.org/10.1007/..
 
?
2

HIV-1 adaptation to NK-cell-mediated immune pressure:

Alter, Galit ; Heckerman, David ; Schneidewind, Arne...
Nature.  476 (2011)  7358 - p. 96-100 , 2011
Link: https://doi.org/10.1038/..
 
?
3

Human leukocyte antigen B27 selects for rare escape mutatio..:

Neumann-Haefelin, Christoph ; Oniangue-Ndza, Cesar ; Kuntzen, Thomas...
Hepatology.  54 (2011)  4 - p. 1157-1166 , 2011
Link: https://doi.org/10.1002/..
 
?
4

In vitro replicative properties of replicons constructed us..:

Oniangue-Ndza, Cesar ; aus dem Siepen, Marc ; Lohmann, Volker...
Virus Research.  142 (2009)  1-2 - p. 1-9 , 2009
Link: https://doi.org/10.1016/..
 
?
5

Protective effect of human leukocyte antigen B27 in hepatit..:

Neumann-Haefelin, Christoph ; Timm, Jörg ; Schmidt, Julia...
Hepatology.  51 (2009)  1 - p. 54-62 , 2009
Link: https://doi.org/10.1002/..
 
?
6

Development and characterization of subgenomic and full-len..:

, 2007
Link: http://nbn-resolving.de/..
 
?
7

Interferon-α and ribavirin resistance of Huh7 cells transfe..:

aus dem Siepen, Marc ; Oniangue-Ndza, Cesar ; Wiese, Manfred...
Virus Research.  125 (2007)  1 - p. 109-113 , 2007
Link: https://doi.org/10.1016/..
 
?
8

EE525 Cost Effectiveness of the Chimeric Antigen Receptor (..:

Deger, K. ; Oniangue-Ndza, C. ; Elsada, A....
Value in Health.  26 (2023)  12 - p. S152-S153 , 2023
Link: https://doi.org/10.1016/..
 
?
9

EE374 Estimating the Impact of Tumors of the Oesophageal an..:

Stoffel, S. ; Bhadhuri, A. ; Köberle, D....
Value in Health.  26 (2023)  12 - p. S123 , 2023
Link: https://doi.org/10.1016/..
 
?
10

HPR181 Comprehensive and Standardized Value Assessment of I..:

Kuhlmey, F. ; Bill, M. ; Fischer, B...
Value in Health.  26 (2023)  12 - p. S285 , 2023
Link: https://doi.org/10.1016/..
 
?
11

EE215 Pharmacoeconomic Analysis of Adjuvant Nivolumab for P..:

Oniangue-Ndza, C ; Strittmatter, G ; Lucas, A...
Value in Health.  25 (2022)  12 - p. S95 , 2022
Link: https://doi.org/10.1016/..
 
?
12

EE463 Cost-Effectiveness of Nivolumab as an Adjuvant Treatm..:

Oniangue-Ndza, C ; Kamgar, F ; Schneider, RP..
Value in Health.  25 (2022)  12 - p. S146 , 2022
Link: https://doi.org/10.1016/..
 
?
13

EE387 Major Ischemic or Hemorrhagic Events and Associated C..:

Oniangue-Ndza, C ; Tao, C ; Dhamane, A
Value in Health.  25 (2022)  12 - p. S131 , 2022
Link: https://doi.org/10.1016/..
 
?
14

PCN111 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILI..:

Oniangue-Ndza, C. ; Gooden, K.M. ; May, J....
Value in Health.  22 (2019)  - p. S457 , 2019
Link: https://doi.org/10.1016/..
 
?
15

PCN208 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TRE..:

Oniangue-Ndza, C. ; Strittmatter, G. ; Orsini, I....
Value in Health.  22 (2019)  - p. S476 , 2019
Link: https://doi.org/10.1016/..
 
1-15